Left ventricular hypertrophy in end-stage renal disease and its possible regression as a result of correction of anemia and arterial hypertension

Terapevticheskii Arkhiv

Volumn 83, Issue 6, 2011, Pages 42-46

  Dzgoeva, F U ^a   Gatagonova, T M ^a   Kadzaeva, Z K ^a   Khamitsaeva, O V ^a   Kochisova, Z Kh ^a   Dzutseva, A T ^a   Bazaeva, B G ^a  

^a Department of Pathological Anatomy   (Russian Federation)

Author keywords

Anemia; End stage renal disease; Left ventricular hypertrophy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; IRON;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RENAL REPLACEMENT THERAPY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMBINED MODALITY THERAPY; ERYTHROPOIETIN; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 79960480834     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Coll B., Betriu A., Martinez-Alonso M. et al. Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment. Nephrol. Dial. Transplant. 2010;25:3017-3025.
2. Hidekazu Moriya, Takayasu Ohtake, Shuzo Kobayashi. Aortic stiffness, left ventricular hypertrophy and weekly averaged blood pressure (WAS) in patients on haemodialysis. Nephrol. Dial. Transplant. 2007;22:1198-1204. (Pubitemid 46523438)
3. Portoles J., Lopes-Gomes J., Aljama P. et al. A prospecteve multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. Nephrol. Dial. Transplan. 2007;22:500-507. (Pubitemid 46189895)
4. Andersson P., Rydberg E., Willenheimer R. Primary hyperparathyroidism and heart disease. Eur. Heart J. 2004;25:1776-1787.
5. Amann K., Tornig J., Kugel B. et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003;63:1296-1301. (Pubitemid 36349995)
6. Tyralla K., Amann K. Cardiovascular changes in renal failure. Blood Purif. 2002;20:462-465. (Pubitemid 35007562)
7. Locatelli F., Pisoni R. L., Combe Ch. et al. Anemia in hemodialysis patients of five European countries: association with morbidity and mortality in DOPPS. Nephrol. Dial. Transplant. 2004;19:121-132. (Pubitemid 38072623)
8. KDOQI Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am. J. Kidney Dis. 2007;50:471-530.
9. Parfrey P. S., Foley R. N., Harriett J. D. et al. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49:1428-1434. (Pubitemid 26166417)
10. Ritz E. The five most cited NTD articles from 1993 to 1999. Nephrol. Dial. Transplant. 2010;25:2814-2817.
11. Covlc A., Goldsmith D. J. A., Covic M. Reduced blood pressure diurnal variability as a risk factor for progressive left ventricular dilatation in hemodialysis patients. Am. J. Kidney Dis. 2000;35:617-623. (Pubitemid 30185505)
12. London G. M. Left ventricular alterations and end-stage renal disease. Nephrol. Dial. Transplant. 2002;17(Suppl. 1):29-36. (Pubitemid 34157116)
13. Amann K., Ritz E. Microvascular disease - the Cinderella of uraemic heart disease. Nephrol. Dial. Transplant. 2000;15:1493-1503.
14. Wizemann V., Blank S., Kramer W. Diastolic dysfunction of the left ventricle in dialysis patients. Contrib. Nephrol. 1994;106:106-109.
15. London G. M. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin. Dial. 2003;16:85-94. (Pubitemid 37356820)
16. Hidekazu Moriya, Takayasu Ohtake, Shuzo Kobayashi. Aortic stiffness, left ventricular hypertrophy and weekly averaged blood pressure (WAS) in patients on haemodialysis. Nephrol. Dial. Transplant. 2007;22:1198-1204. (Pubitemid 46523438)
17. Krasniak A., Drozdz M., Pasowicz M. et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol. Dial. Transplant. 2007;22:515-521. (Pubitemid 46193946)
18. Kiyoshi Maekawa, Tetsuo Shqji, Masanori Emoto et al. Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol. Dial. Transplant. 2008;23:2329-2336. (Pubitemid 351957581)
19. Cottone S., Lorito M. C., Riccobene R. et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J. Nephrol. 2008;21:175-179.
20. Andersson P., Rydberg E., Willenheimer R. Primary hyperparathyroidism and heart disease. Eur. Heart J. 2004;25:1776-1787.
21. Block G. A., Hulbert-Shearon T. E., Levin N. W., Port F. K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998;31:607-617.
22. Amann K., Breitbach M., Ritz E., Mall G. Myocytc/capillary mismatch in the heart of uremic patients. J. Am. Soc. Nephrol. 1998;9:1018-1022.
23. Zipes D. P., Libby P., Bonow R. O., Braunwald E. Braunwald's heart disease: A textbook of cardiovascular medicine. Philadelphia, RA: Elsevier Saunders; 2005. 492-496.